Proton pump inhibitors are typically used to treat dyspepsia and prevent gastrointestinal bleeding among patients prescribed antiplatelet therapy, but new research shows PPIs are associated with numerous adverse events, including increased risk of chronic kidney diseases and kidney injury.
Researchers analyzed a collection of data gathered on the adverse effects of PPIs and the resulting study was published in JAMA Internal Medicine.
One study of data collected from more than 10,400 patients over more than 13 years revealed the risk of chronic kidney disease was 50 percent higher in patients who used PPIs than in nonusers.
Another study that included data from more than 290,000 patients found the risk of acute kidney injury and acute intestinal nephritis was two and a half to three times higher in PPI users and renal disease was two times more common in users than nonusers.
This is just the latest study in a series of mounting evidence that associates PPIs with adverse events, according to the JAMA study authors.